A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Clinical trial NCT02551874 · COMPLETED
Trial details
- NCT number
- NCT02551874
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-20
- Primary completion
- 2017-05-08
- Enrollment
- 650
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.